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Abstract
Background: Pathological stage and grade have limited ability to predict the outcomes of superficial urothelial
bladder carcinoma at initial transurethral resection (TUR). AT-motif binding factor 1 (ATBF1) is a tumor suppressive
transcription factor that is normally localized to the nucleus but has been detected in the cytoplasm in several
cancers. Here, we examined the diagnostic value of the intracellular localization of ATBF1 as a marker for the
identification of high risk urothelial bladder carcinoma.
Methods: Seven anti-ATBF1 antibodies were generated to cover the entire ATBF1 sequence. Four human influenza
hemagglutinin-derived amino acid sequence-tagged expression vectors with truncated ATBF1 cDNA were constructed
to map the functional domains of nuclear localization signals (NLSs) with the consensus sequence KR[X10-12]K. A total
of 117 samples from initial TUR of human bladder carcinomas were analyzed. None of the patients had received
chemotherapy or radiotherapy before pathological evaluation.
Results: ATBF1 nuclear localization was regulated synergistically by three NLSs on ATBF1. The cytoplasmic fragments of
ATBF1 lacked NLSs. Patients were divided into two groups according to positive nuclear staining of ATBF1, and significant
differences in overall survival (P = 0.021) and intravesical recurrence-free survival (P = 0.013) were detected between ATBF1
+ (n = 110) and ATBF1− (n = 7) cases. Multivariate analysis revealed that ATBF1 staining was an independent prognostic
factor for intravesical recurrence-free survival after adjusting for cellular grading and pathological staging (P = 0.008).
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Conclusions: Cleavage of ATBF1 leads to the cytoplasmic localization of ATBF1 fragments and downregulates nuclear
ATBF1. Alterations in the subcellular localization of ATBF1 due to fragmentation of the protein are related to the
malignant character of urothelial carcinoma. Pathological evaluation using anti-ATBF1 antibodies enabled the
identification of highly malignant cases that had been overlooked at initial TUR. Nuclear localization of ATBF1
indicates better prognosis of urothelial carcinoma.
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Background
Transurethral resection (TUR) is a standard initial treat-
ment for urothelial carcinoma (UC) of the bladder.
Approximately 70 % of UC of the bladder is superficial
at initial diagnosis. However, approximately 60 % of pa-
tients with superficial UC experience recurrence and
10–20 % progress to invasive cancer [1]. Standard prog-
nostic features, such as pathological stage and grade,
have limited ability to predict disease outcomes [2],
underscoring the need to identify accurate markers to
predict the prognosis of UC.
The AT-motif binding factor 1 (ATBF1, ZFHX3) gene
was originally identified as a suppressor of α-fetoprotein
(AFP) gene transcription and shown to function by
binding to the AT-rich element in the promoter region
[3, 4]. Frequent genomic mutations of chromosome
16q23 at the ATBF1 gene locus are found in prostate
cancer [5, 6]. The loss of ATBF1 is associated with the
malignant character of AFP-producing gastric cancer
[7], which is characterized by loss of heterozygosity at
the ATBF1 locus [8]. By contrast, ATBF1 mutations are
not frequently detected in human breast cancer, in
which ATBF1-A mRNA levels are regulated at the tran-
scriptional level and not by genetic mechanisms, deletions,
or mutations [9, 10]. ATBF1 is frequently detected in the
cytoplasm in many types of cancer [11–13]. Loss of the
nuclear localization of ATBF1 is associated with the histo-
pathologic progression of head and neck squamous cell
carcinoma [12]. However, the prognostic value of ATBF1
in patients with UC has not been investigated to date.
The aim of the present study was to examine the prog-
nostic value of ATBF1 as a marker for predicting overall
survival and recurrence-free survival in patients with
UC. The prognostic value of ATBF1 was examined by
histopathological staining, and the molecular mecha-
nisms regulating the subcellular localization of ATBF1
were investigated. The expression of ATBF1 was exam-
ined in human UC tissue specimens and cell lines by
generating seven anti-ATBF1 antibodies covering the en-
tire 404-kDa ATBF1 protein to clarify the mechanism of
cleavage of ATBF1 in cancer cells. Our results indicate
that the anti-ATBF1 antibodies can be used to identify
highly malignant cases at initial TUR.
Results
Mislocalization of ATBF1 in human UC cells
The transcription factor ATBF1 is a DNA-binding
protein that is primarily localized in the nucleus and is
involved in brain development; it regulates the expres-
sion of genes involved in cell cycle arrest and cell dif-
ferentiation [14, 15]. Screening of tissue sections from
patients with UC by immunohistochemistry detected
ATBF1 expression in the nucleus (Fig. 1a) and cyto-
plasm (Fig. 1b) using the same anti-ATBF1 antibody
[14].
To determine whether the detection of ATBF1 in the
cytoplasm could be attributed to the presence of ATBF1
fragments, seven specific antibodies against different
ATBF1 peptides from the N-terminus to the C-terminus
were generated to improve the accuracy of detection
(Fig. 2A). The reactivity of these seven anti-ATBF1 anti-
bodies against the ATBF1 protein was verified by west-
ern blot analysis in HEK293T cells expressing ATBF1
(Additional file 1: Figure S1). These antibodies detected
ATBF1 in the different subcellular compartments of UC
cells (Fig. 2B). The N- and C-terminal regions were fre-
quently detected in the cytoplasm, whereas the middle
sections of ATBF1 were detected in the nucleus. Based
on these results, samples were divided into eight groups
according to the positive nuclear staining for ATBF1, as
detected by the seven independent anti-ATBF1 anti-
bodies (Fig. 2B).
Nuclear expression of ATBF1 predicts better clinical
prognosis of human UC
The anti-ATBF1 antibodies detected positive cytoplas-
mic ATBF1 staining and negative nuclear staining in
cancer cells, whereas normal cells expressed ATBF1 in
the nucleus. To determine whether the extent of nuclear
staining (Fig. 2B) was correlated with the degree of ma-
lignancy of UC, the survival of patients was analyzed by
the Kaplan–Meier method. The results indicated that
nuclear expression of ATBF1 was associated with better
clinical prognosis of human UC regarding overall sur-
vival and intravesicular recurrence-free survival over a
period of 10 years (Fig. 3).
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Nuclear ATBF1 expression is associated with
pathological stage
A total of 117 primary tumors (Table 1) were screened
using ATBF1 antibodies to clarify the relationship
between ATBF1 and pathological stage. Spearman cor-
relation analysis of nuclear ATBF1 staining and patho-
logical staging in the order of low cellular grade pTa,
high cellular grade pTa, pT1, and pTis showed that
the correlation coefficient was −0.601, (P < 0.001)
(Table 2). These results suggested that the subcellular
localization of ATBF1 is correlated with the degree of ma-
lignancy of UC. Multivariate analyses (Tables 3 and 4)
indicated that ATBF1 staining is a novel independent






Fig. 1 Two distinct subcellular localizations of ATBF1. a, UC cells
expressing ATBF1 in the nucleus (N). b, UC cells expressing ATBF1
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Fig. 2 Anti-ATBF1 antibodies specifically detect distinct sections of ATBF1 localized in the nucleus or cytoplasm of UC cells. A, Map of the
antigenic domains of the ATBF1 amino acid sequence. MB33, 16–45 aa; MB34, 238–255 aa; MB39, 1504–1520 aa; D1-120, 2114–2147 aa; MB44,
2229–2245 aa; MB47, 2759–2775 aa; MB49, 3410–3426 aa. B, Left side of the line characters a–h indicates independent cases of UC. Right side
of the fraction numbers 7/7–0/7: numerators represent the number of antibodies to detect ATBF1 in the nucleus and the denominators represent the
total number of antibodies (which is the fixed number 7). Scale bar = 5 μm
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after adjusting for cellular grade and pathological stage (P
= 0.008), whereas it is not a significant prognostic factor
for overall survival (P = 0.538). Of the 117 patients, 10 and
22 (Table 1) were treated with intravesical instillation of
Bacille de Calmette et Guérin (BCG) and anti-cancer
drugs following TUR-BT, respectively, which had no effect
on overall survival (Kaplan–Meier method, Log rank test,
P = 0.670 and 0.191, respectively). In addition, 16 patients
received radical cystectomy, which had an adverse effect
on overall survival (Kaplan–Meier method, Log rank
test, P = 0.0004). Although histological grade did not
differ between patients with and without radical cystec-
tomy (chi-square test, P = 0.132), those who underwent
radical surgery had higher T stage at TUR than patients
without surgery (chi-square test, P = 0.019).
Multiple nuclear localization signals (NLSs) drive the
nuclear localization of ATBF1
Three NLSs were identified (Fig. 4b) in addition to NLS
2615–2617 [16]. The function of each NLS (1387–1400,
2947–2959, and 2987–3005) was analyzed by generating
fusion proteins with green fluorescent protein (GFP)
(Fig. 4a1). Tandem repeat analysis of these two NLSs
(2947–2959 and 2987–3005) showed a high concentra-
tion of GFP fusion protein in the nucleus (Fig. 4a5).
A series of HA-tagged ATBF1 expression vectors with
and without the NLSs were constructed (Fig. 5a), and
the subcellular localization of these truncated ATBF1
fragments was traced by detecting the HA-tag to differ-
entiate them from the intrinsic ATBF1 protein. Frag-
ments lacking the NLSs at the N- and C-terminus were
detected mainly in the cytoplasm (Fig. 5b, images 4, 6,
10, and 12), whereas the middle section of the ATBF1
fragment with the NLS was detected in the nucleus
(Fig. 5b, images 7 and 9), similar to the full-length
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Fig. 3 Nuclear staining of ATBF1 is a favorable indicator of patient survival. The 117 patients were divided into two groups according to ATBF1
nuclear staining (110 cases in the positive group and seven in the negative group). a, Overall survival according to nuclear staining of ATBF1 after
10 years by Kaplan–Meier analysis. b, Intravesicular recurrence-free survival analyzed under the same conditions as overall survival
Table 1 Characteristics of patients with UC included in the
study
Age at diagnosis, mean (range) 69.6 years (36–93)
Gender, male 94 cases (80.3 %)
pT stage at initial TUR
pTa 92 cases (78.6 %)
pT1 15 cases (12.8 %)
pTis 10 cases (8.6 %)
Cellular grade at initial TUR
Low 57 cases (48.7 %)
High 60 cases (51.3 %)
Intravesical BCG therapy 11 cases
Intravesical chemotherapy (epirubicin) 21 cases
Total cystectomy 16 cases
Bladder cancer-specific mortality 6 cases
All-cause mortality 21 cases
BCG, Bacille Calmette–Guérin
Table 2 Correlation analysis between nuclear staining of ATBF1
and pathological stage
Pathological stage (cellular grade)




6/7 18 15 5
5/7 6 4 1
4/7 6 2 2
3/7 1 1
2/7 6 4 5
1/7 1
0/7 1 2 4
Spearman correlation analysis revealed a significant association (coefficient of
correlation = −0.601, P < 0.001)
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blot analysis of HA-tagged nuclear and cytoplasmic pro-
tein fractions were consistent with those of microscopic
observation. The full-length and middle parts of the
ATBF1 fragment containing NLSs were mainly detected
in the nuclear fraction (Fig. 5c, lanes 2 and 4). The N-
and C-terminal fragments of ATBF1 were strongly de-
tected in the cytoplasmic fraction (Fig. 5c, lanes 8 and
10).
ATBF1 localizes to the nucleus or cytoplasm by internal
cleavage to produce protein with or without NLSs
We expected to observe full-length ATBF1 exclusively in
the nucleus. Because the expression vector was designed
to produce an HA-tagged ATBF1 fusion protein, the
subcellular localization of the HA-tag and ATBF1
should be the same. Fragments with NLSs localized to
the nucleus and fragments without NLSs localized to
the cytoplasm (Fig. 5b). Both the antibody against
ATBF1 and HA-tag should appear in the nucleus
(Fig. 6a, images 1–4). However, anti-HA-tag antibody
staining was detected in the cytoplasm (Fig. 6a, images
6–8) in addition to anti-ATBF1 antibody staining in the
nucleus (Fig. 6a, images 5, 7, and 8). The ATBF1 pro-
tein must be expressed as a single molecule including
the HA-tag. This paradoxical observation suggested
that the protein underwent cleavage in to at least two
fragments fragments with and without NLSs (Fig. 6b).
Discussion
The transcription factor ATBF1 is mainly expressed in
the nucleus, although it is frequently expressed in the
cytoplasm of cancer cells [12, 13]. In the present
study, we show that abnormal subcellular localization
of ATBF1 in UC is derived from cleavage of ATBF1 to
produce smaller fragments. Fragments of ATBF1 with
NLSs localized to the nucleus, whereas fragments
lacking NLSs were retained in the cytoplasm. Three
NLSs (1387–1400, 2947–2959, and 2987–3005) were
identified, in addition to the previously reported NLS
2615–2617 [16]. Although each NLS functions inde-
pendently to drive the nuclear localization of the pro-
tein, a single NLS signal has weak activity. Tandem
repeated NLSs enable efficient nuclear transportation.
Because ATBF1 is large, the cooperation of multiple
NLSs is needed for efficient localization to the nu-
cleus. We found that a small N-terminal fragment of
ATBF1 was released to the cytoplasm and separated
from the major part of ATBF1 in the nucleus (Fig. 6).
The malignant character of cancer cells may result in
the cleavage of ATBF1 to produce fragments localized
to the cytoplasm (Additional file 2: Figure S3).
The mechanism underlying the generation of ATBF1
fragments in cancer cells remains unclear, and the precise
cleavage sites and enzymes responsible are unknown at
present. This was one of the limitations of our present
study. We speculate that the function of these abnormal
fragments in the cytoplasm is to inhibit the function of in-
tact ATBF1 in the nucleus. Previous studies showed that
phosphatase treatment to reduce the phosphorylation of
ATBF1 enhances the sensitivity to calpain and induces the
degradation of ATBF1 [17]. However, there are no studies
reporting increased activity of phosphatases in UC. On
the contrary, alkaline phosphatase levels are low in T24
bladder cancer cells [18], which are used as the most ma-
lignant model of UC. This suggests that alkaline phosphat-
ase levels are not the main cause of ATBF1 instability in
T24 bladder cancer cells, and ATBF1 fragmentation could
be mediated by an as yet unknown mechanism in T24
bladder cancer cells (Additional file 3: Figure S2).
The pathological evaluation of ATBF1 staining was
consistent with the WHO classification of UC. A
decrease in the nuclear localization of ATBF1 was
associated with an increased degree of malignancy of
UC. Pathological evaluation of ATBF1 is an effective
method for detecting highly malignant cases, specifically
in low-grade cases at the initial diagnosis by classical
hematoxylin and eosin staining. Radical treatment of these
cases at the initial stages could improve survival rates by
suppressing invasion and metastasis in the long term. This
Table 3 Multivariate analysis of risk of overall survival
Variables HR 95 % CI P
Pathological stage pTis 1 0.053
pTa 0.278 0.061–1.268
pT1 1.292 0.319–5.238
Cellular grade Low 1 0.879
High 1.104 0.309–3.935
ATBF1 staining Positive 1 0.538
Negative 1.556 0.381–6.359
P values by Cox’s proportional hazards model
HR hazard ratio, CI confidence interval
Table 4 Multivariate analysis of risk of intravesical recurrence-free
survival
Variables HR 95 % CI P
Pathological stage pTis 1 0.021*
pTa 2.709 0.678–10.822
pT1 5.575 1.458–21.321
Cellular grade Low 1 0.713
High 1.133 0.582–2.206
ATBF1 staining Positive 1 0.008*
Negative 5.394 1.561–18.638
P values by Cox’s proportional hazards model
HR hazard ratio, CI confidence interval
*Significant P values by Cox’s proportional hazards model
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hypothesis should be further evaluated in future clinical
trials to test its accuracy.
The malignant characteristics of T24 bladder cancer
cells require activation of signal transducer and activator
of transcription (STAT)3 for epidermal growth factor in-
duction of matrix metalloproteinase-1 and −10 (strome-
lysin-2). Furthermore, expression of dominant-negative
STAT3 is sufficient to inhibit cell migration, invasion,
and tumor formation in nude mice [19]. These results
demonstrate that STAT3 phosphorylation plays a crucial
role in the malignant characteristics of T24 bladder can-
cer cells. LIV1 (SLC39A6: solute carrier family 39 zinc
transporter member 6), a breast-cancer-associated zinc
transporter protein, is a downstream target of STAT3
that is essential and sufficient for the cell-autonomous
role of STAT3 in the epithelial-mesenchymal transition
(EMT) of zebrafish gastrula organizer cells [20]. LIV1 is
essential for the nuclear localization of the zinc-finger
protein Snail, a master regulator of EMT, to suppress
E-cadherin. These results establish a molecular link
between STAT3, LIV1, and Snail in EMT [20]. ATBF1
inhibits STAT3 signaling by interacting with protein
inhibitor of activated STAT3 [21]; therefore, the frag-
mentation of ATBF1 may induce STAT3 hyper-
activation and EMT (Additional file 4: Figure S4B).
Based on traditional histopathological examinations,
patients with potentially highly malignant disease re-
ceived radical cystectomy. It was evident that the ad-
verse effects of radical surgery were not related to
poorer survival outcomes. In current clinical practice,
radical surgery for those with possible highly malignant
disease does not improve survival compared with that
in patients who are regarded as having clinocopatholo-
gically indolent disease without the need for surgery.
Thus, for patients with possible malignant histopath-
ology, we cannot provide additional usable information
on traditional examinations. However, we found that
the status of ATBF1 was predictive of lethal disease
among those initially diagnosed with low malignant po-
tential cancers; prompt discrimination of patients with
potentially highly malignant disease using the new tech-
nology with the ATBF1 assay may lead to more efficient
surgical treatment and superior prognostic outcomes.
Conclusions
The mislocalization of ATBF1 in malignant UC cells is
caused by the cleavage of the ATBF1 protein into frag-
ments rather than the specific subcellular localization of
the protein. Fragments containing a NLS localize to the
nucleus, whereas those lacking a NLS are retained in the
cytoplasm. Alteration of the subcellular localization of
these distinct fragments of ATBF1 is related to the ma-
lignant character of UC. Pathological evaluation using
anti-ATBF1 antibodies is an effective method to identify
malignant cases that are overlooked at initial TUR.
Methods
Patients
A total of 141 patients who were admitted to the Niigata
Rosai Hospital between January 1997 and October 2006
were clinically suspected of having UC of the bladder.
The study focused on UC malignancy at the superficial
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Fig. 4 NLS synergistically drives GFP into the nucleus. Three NLSs were fused with the enhanced GFP (EGFP) gene and transfected into COS-7
cells. a, The numbers above the panels indicate the site of the NLSs by amino acid number on the ATBF1 protein. The ratio indicated below the
panels shows the intensity of luminescence in cytoplasm (C) and nucleus (N). Panel 5 shows the synergistic effect of NLSs achieved by the
tandem repeat of NLS 2947–2959 and NLS 2987–3005 to generate NLS 2947–3005. b, Amino acid sequences of NLS 1387–1400, NLS 2947–2959, and
NLS 2987–3005, and the tandem repeated NLS 2947–3005. Green letters indicate the consensus sequence as an NLS
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stage for better choice of treatment and to achieve better
prognosis. One hundred and thirty patients were diag-
nosed with superficial UC of the bladder according to
the updated WHO and TNM classifications [22]. Diag-
nosis was made by three pathologists certified by the
Japanese Society of Pathology. Two pathologists (Y.I.
and K.T.) made the initial diagnosis, which was con-
firmed by M.K. When a clear classification was difficult,
M.K. re-evaluated the evidence and made the final deci-
sion regarding classification. All samples obtained from
initial TUR were formalin-fixed, paraffin-embedded
blocks and were suitable for immunohistochemical ana-
lysis. Eleven patients with combined adenocarcinoma,
squamous cell carcinoma, carcinosarcoma or anaplastic
carcinoma were excluded. Two patients with insufficient
clinicopathological data were also excluded. Follow-up
details were available for 117 patients with superficial
UCs. The follow-up period ranged from 1 to 120 months
(median, 55 months). None of the patients received
chemotherapy or radiotherapy before initial TUR.
Cell lines
The bladder cancer cell lines RT4, HT1376, and T24
were obtained from the American Type Culture Collec-
tion (ATCC). The cells were maintained in RPMI-1640
medium supplemented with 10 % fetal bovine serum in
a 37 °C, 5 % CO2 humidified incubator. Cell growth was
measured by MTT conversion assay (Chemicon Inter-
national, Temecula, CA, USA). Absorbance was evalu-
ated in triplicate at 490 nm using a Multiplate Reader
(Bio Rad, Hercules, CA, USA). COS-7 and HEK293 cells
were obtained from ATCC, and cultured in Dulbecco’s
modified Eagle’s medium (i; low glucose) containing
10 % fetal bovine serum without antibiotics. These cells
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a Fig. 5 Fragments without NLS at the N- and C termini localized tothe cytoplasm and fragments with NLS localized to the nucleus. a,
Map of four HA-tagged ATBF1 expression vectors. HA-ATBF1 consisted
of full-length ATBF1 cDNA. ATBF1-2.7 N consisted of 2.7-kbp of
N-terminal cDNA. ATBF1-7.2 M consisted of 7.2-kbp of cDNA from
the middle section encoding three NLS sequences exclusively.
ATBF1-1.2C consisted of 1.2-kbp of C-terminal cDNA. The HA tag
was localized at the N terminus of the ATBF1 expression vectors.
The sites of the three NLSs are indicated by red triangles. b, Overexpression
studies in HEK293T cells. HA-ATBF1 expressed the HA tag in the
nucleus. ATBF1-2.7 N expressed the HA tag in the cytoplasm.
ATBF1-7.2 M expressed the HA tag in the nucleus. ATBF1-1.2C
expressed the HA tag in the cytoplasm. Scale bar = 5 μm. c, Full-length
ATBF1 protein derived from HA-ATBF1 observed mainly in the nucleus.
Truncated protein expressed by the N-terminal 2.7-kbp cDNA observed
in the cytoplasmic fraction. Truncated protein expressed by the middle
7.2-kbp cDNA observed in the nuclear fraction. Truncated protein
expressed by the C-terminal 1.2-kbp cDNA observed in the cytoplasmic
fraction. Lamin A is a nuclear marker and α-tubulin is a cytoplasmic marker
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Transfection and plasmid constructs
To generate expression vectors containing the GFP
gene fused with DNA fragments encoding NLSs (1387,
2947, 2987, and 2947 + 2987), four oligomer sets were
prepared to produce NLSs including the fragments as
follows: for NLS 1387, 4798U: gcccttcagacgcattttaat and
4906 L: tcttgaaggccaggctacac; for NLS2947, 9469U:
tctgcaggcaaatctggtga and 9619 L: gtcattgcccaggacgtgac;
for NLS2987, 9616U: attggactgccaaagagagt and 9741 L:
tttgggtccctcataactgc; for NLS2947 + 2987, 9469U: tctgca
ggcaaatctggtga and 9741 L: tttgggtccctcataactgc. These
polymerase chain reaction products were subcloned
into pGEM-T Easy (Promega, Madison, WI, USA) and
then subcloned into the MCS (EcoRI-XbaI) site of
pEGFP-C1 (Clontech, Takara Bio Inc., Otsu, Shiga,
Japan). These expression vectors were transfected into
COS7 cells. A series of truncated ATBF1 cDNA
expression vectors was prepared from the full-length
ATBF1 expression vector pHA-ATBF1 [15, 21, 23]. The
truncated ATBF1 cDNA sequences were prepared by
digestion with the following enzymes: SalI and BamHI
(1–892 aa), BamHI and SfiI (893–3288 aa), and SfiI and
NotI (3289–3703 aa). Each fragment was subcloned
into pCI-HA [15] and digested with SalI and NotI using
oligolinker-mediated ligation. These vectors were trans-
fected into HEK 293 T cells using TransIT-293 T re-
agent (Mirus Bio, Madison, WI, USA) on tissue culture
dishes. Cells were placed on glass slides coated with
combinations of poly-L-lysine (Sigma, St Louis, MO,
USA) for microscopic analysis.
Anti-ATBF1 antibodies
The seven antibodies used in this study were rabbit
polyclonal antibodies produced against polypeptides
ATBF1 HA ATBF1/HA ATBF1/HA/DAPI
1 2 3 4



















Fig. 6 Subcellular localization of the N- and C-terminal sections of ATBF1. HEK293T cells were transfected with a HA-tagged full-length ATBF1
cDNA expression vector to observe ATBF1 under the confocal microscopy. An anti-ATBF1 antibody (D1-120) detected the middle section of ATBF1
in the nucleus (A1, A3, A4, A5, A7, A8). a, Most (29/30) of the cells expressed HA-tags in the nucleus with the middle part of ATBF1 (A2–A4). One
cell (1/30) showed an HA-tag in the cytoplasm in contrast to ATBF1 in the nucleus (A6–A8). Scale bar = 5 μm. b, Schematic explaining the
mechanism of abnormal localization of the N-terminal fragment of ATBF1 cleaved from the main sequence of ATBF1. The HA-tagged N-terminal
fragment should be shorter than the ATBF1 protein retained in the cytoplasm. The main fragment of ATBF1 containing three NLSs (1387, 2947
and 2987) should be localized in the nucleus. The epitope of D1-120 represents the major section of ATBF1 containing three NLSs
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designed based on the amino acid sequence of human
ATBF1. The polypeptides used were as follows: amino
acid residues 16–45 (MB33), 238–255 (MB34), 1504–
1520 (MB39), 2229–2245 (MB44), 2759–2775 (MB47),
and 3410–3426 (MB49) (Fig. 5a). An antigen for D1-
120 (MBL, Nagoya, Japan) corresponding to human
ATBF1 amino acid residues 2107–2147 was produced
as a glutathione-S-transferase fusion protein.
Western blot analysis
Western blot analysis was performed on protein ex-
tracts that were separated into nuclear and cytoplasmic
fractions as described by Dignam et al. [24]. Protein
concentration was measured using the Bradford assay
kit (Bio-Rad). Each sample was separated on a 4–20 %
gradient sodium dodecyl sulfate polyacrylamide gel
(Bio-Rad), and transferred to a polyvinylidene difluoride
membrane (Millipore, Billerica, MA, USA). The mem-
brane was blocked with 5 % bovine serum albumin
(Fraction V; Sigma) in Tris-buffered saline containing
0.05 % Tween 20 for 1 h, and then incubated with pri-
mary antibodies for 1 h at room temperature. All anti-
bodies were diluted in 1 % bovine serum albumin in
Tris-buffered saline containing 0.05 % Tween 20. Rabbit
polyclonal anti-ATBF1 antibody (antibody D1-120 in
Fig. 5a; MBL, dilution 1:1000), anti-SOD antibody (Cu–Zn
superoxide dismutase-1, dilution 1:1000; Stressgen,
Sapphire Bioscience, Waterloo, WA, Australia), and
anti-histone H3 antibody (dilution 1:150; Abcam, San
Francisco, CA, USA) were used. Next, the membrane
was incubated with a secondary antibody, goat anti-
rabbit IgG (H + L-chain)-HRP antibody at 1:2000
(MBL) or sheep anti-mouse IgG/horseradish peroxidase
(Amersham GE Healthcare, Bucks, UK, dilution 1:1000)
for 1 h at room temperature, and visualized using
Amersham ECL Plus (GE Healthcare) and an LAS-3000
image analyzer (Fuji Photo Film, Tokyo, Japan).
Immunohistochemistry
The 5-μm sections of paraffin-embedded tissues and the
cell blocks were deparaffinized and rehydrated by the
following procedure. Antigen was retrieved with a
citrated buffer (0.01 M, pH 6.0) at 110 °C for 4 min in a
pressure cooker. Sections were incubated with methanol
containing 0.3 % H2O2 and 1.0 % sodium azide to block
endogenous peroxidase activity, and then incubated with
the seven anti-ATBF1 antibodies for 1 h. Antibody dilu-
tions were as follows: MB33 (1:50), MB34 (1:100), MB39
(1:300), D1-120 (1:300), MB44 (1:120), MB47 (1:10), and
MB49 (1:5). Staining was carried out at room
temperature. Immunoreactive products were detected
with an anti-rabbit IgG antibody (Envision labeled poly-
mer; Dako Cytomation, Kyoto, Japan) and visualized by
diaminobenzidine chromogen. Tissue sections were
counterstained with hematoxylin.
Immunocytochemistry
Cells were fixed in 4 % paraformaldehyde in phosphate-
buffered saline (PBS) at room temperature for 20 min,
then washed with 0.25 % Triton-X in PBS, and blocked
with 10 % normal goat serum. Cells were then incubated
for 1 h at room temperature with primary antibodies
against ATBF1 (D1-120; MBL), β-tubulin III (Sigma), and
HA-tag (MBL). After three washes with 0.25 % Triton-X
in PBS, cells were visualized using the following secondary
antibodies: Alexa 488-conjugated goat anti-mouse, Alexa
546-conjugated goat anti-rabbit IgG, Alexa 488-
conjugated goat anti-rat, and Alexa 546-conjugated goat
anti-rat IgG (Molecular Probes, Eugene, OR, USA). Sec-
tions were incubated for 1 h in the dark, and after two
washes with PBS, subjected to nuclear staining with 4′,6-
diamidino-2-phenylindole (Wako, Osaka, Japan) for 5 min.
Pathological evaluation
The immunoreactivity of ATBF1 was tested on normal hu-
man urothelium by immunohistochemistry, and on
HEK293T cells with and without ATBF1 expression vector
by Western blot analysis (Additional file 1: Figure S1). We
used a malignant tumor lesion showing the most serious
atypia in pTa and pTis. In addition, the most deeply in-
vaded lesion in the submucosal area in pT1 was selected. In
cases with multiple foci of different grades of cancer, we
chose the lesion with the highest malignancy grade. In cases
of pTa tumors concomitant with a pTis tumor, the pTis
tumor was used to make a diagnosis. In cases of a pT1
tumor concomitant with pTa tumors, the pT1 tumor was
chosen for the diagnosis.
Statistical analysis
Spearman correlation analysis was used to examine the
correlation of ATBF1 nuclear staining with pathological
status of UC. The Kaplan–Meier method and the log-rank
test were used to analyze differences in overall survival or
recurrence-free survival between different staining groups.
The association of clinicopathological parameters with the
risk of overall survival and intravesical recurrence-free
survival was evaluated by the Cox proportional hazards
model. A value of P < 0.05 was regarded as significant. All
analyses were performed using SPSS version 16.0 (Softo-
nic, Chicago, IL, USA) and Prism 4.0 (GraphPad Software,
La Jolla, CA, USA) on a Windows-based computer.
Additional files
Additional file 1: Figure S1. Specificity and sensitivity of the seven
anti-ATBF1 antibodies. Western blot analysis of ATBF1 in HEK293T cells
using the seven anti-ATBF1 antibodies (Fig. 5a MB33, MB34, MB39,
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D1-120, MB44, MB47 and MB49). Lanes 1, 3, 5, 7, 9, 11, and 13 represent
HEK293T cells with an HA-tag expression vector (pCI-HA). Lanes 2, 4, 6, 8, 10,
12, and 14 represent HEK293T cells containing an HA-tagged ATBF1
expression vector (pCI-HA-ATBF1). HEK293T cells were grown in
DMEM supplemented with 10 % fetal bovine serum at 37 °C and 5 %
CO2. HEK293T cells were transfected with the HA-tagged expression
vector or the HA-tagged ATBF1 expression vector (HA-ATBF1) using
transIT-293 reagent. (PPTX 215 kb)
Additional file 2: Figure S3. Schematic explanation of the correlation
between the mislocalization of ATBF1 and the malignant characteristics
of cancer cells. The transcription factor ATBF1 is a DNA-binding protein
found in the nucleus that regulates the transcription of genes inducing
cell cycle arrest. Cleavage of ATBF1 should impair the physiological function
of ATBF1 in the nucleus as an inhibitory factor against carcinogenesis.
Cleaved fragments with no NLSs indicate the malignant character of
cancer cells. (PPTX 49 kb)
Additional file 3: Figure S2. A, T24 cells showed the most malignant
staining pattern of ATBF1 (Fig. 2B) and HT1376 showed the most benign
staining pattern (Fig. 2B) similar to the staining pattern of RT4. RT4 is a
cell line derived from non-malignant papilloma. Scale bar = 5 μm. B,
Western blot analysis of D1-120 showed the loss of ATBF1 in T24 cells.
The result is relevant to the pathological staining with D1-120 regarding
the loss of ATBF1 in the nucleus and cytoplasm. RT-4 and HT1376 cells
expressed smaller fragments of ATBF1 in the cytoplasm and larger
fragments of ATBF1 in the nucleus. The results suggest that the ATBF1
in the cytoplasm was not the full length but fragments of ATBF1. C,
T24 cells, which expressed no ATBF1 in the nucleus, grew faster than
the other two cell lines expressing ATBF1 in the nucleus. (PPTX 493 kb)
Additional file 4: Figure S4. ATBF1 is highly expressed in cells at the
epithelial zone associated with the expression of E-cadherin. A, Pathological
specimens of bladder carcinoma were stained by hematoxylin and
eosin, E-cadherin, and anti-ATBF1 antibodies (MB33, MB34, MB39,
D10120, MB44, MB47 and MB49). Bladder lumen (L), epithelial zone (E),
and mesenchymal zone (M) are shown. A transition from higher expression
of ATBF1 in the E zone to lower expression of ATBF1 in the M zone was
observed. The basement membrane is not clear between the E and M
zones because of invasive cancer. Scale bar = 5 μm. B, Schematic ex-
planation of the function of ATBF1 in inducing E-cadherin. ATBF1 in-
teracts with protein inhibitor of activated STAT3 (PIAS3) to suppress
STAT3 signaling [21]. Activation of STAT3 should activate the zinc
transporter LIV1 and introduce zinc ions into the cells. The zinc ion is
a regulatory factor for Snail to suppress E-cadherin. Therefore, zinc
transporters play an important role in the migration of cells during
embryogenesis [20]. Fragments of ATBF1 may have a dominant negative
effect on suppressing STAT3, whereas they promote STAT3 signaling and
suppress the expression of E-cadherin, which might be the basis of invasion
and metastasis. (PPTX 1682 kb)
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